Videos
Cannabis Investing Newsletter
September 22, 2023
Menu
An artist illustration of a doctor holding lungs. The FDA granted orphan-drug status for KB408 in September for the treatment of serious lung disease caused
A 3D illustration showing abundant lymphoblasts in blood. Enrylaze, sold as RylaZe in the US and Canada, was approved by the US Food and Drug
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s
The WHO and World Bank estimate that the slow progress towards UHC stated in the report is associated with the emergence of Covid-19. Credit: Chinnapong
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal
Toronto, Ontario–(Newsfile Corp. – September 22, 2023) – Safe Supply Streaming Co. Ltd. (formerly Origin Therapeutics Inc.) (“Safe Supply” or the “Company“) is pleased to announce
Johnson & Johnson’s nipocalimab (M-281) is under clinical development in Phase II for rheumatoid arthritis. Credit: one photo via Shutterstock. The patent for Janssen’s second-generation,
Cybin Inc. CYBN has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD.)